Year: 2017
Type: article
Study design: Case Report
Abstract: (See page 632 for the Photo Quiz.) Diagnosis: Pulmonary Kaposi sarcoma (KS). This patient with a history of end-stage human immunodeficiency virus (HIV)/AIDS, antiretroviral therapy (ART) noncompliance, and a diagnosis of KS based upon prior retroperitoneal lymph node biopsy presented with new-onset pulmonary symptoms accompanied by bilateral ill-defined pulmonary nodular and flame-shaped densities, patchy consolidations, and hilar lymphadenopathy on chest computed tomography. The differential diagnoses should include both infectious and noninfectious causes, such as atypical bacteria (Pneumocystis pneumonia), mycobacteria (tuberculosis and atypical mycobacteria), fungal infection, lymphoma, and KS. Pathology report of the wedge biopsy of the patient’s right upper lobe revealed multiple foci of KS that varied in diameter from 0.2 to 0.5 cm with an aggressive feature as defined by >20 mitotic figures/10 high-power fields in the tumor cells. Immunohistochemical staining demonstrated that the tumor cells were positive for human herpesvirus 8 (HHV-8), which is confirmatory for a diagnosis of KS (Figure 1). Additionally, staining of tumor cells was positive for ERG and CD34, which are expressed in malignant vascular endothelial neoplasms (including both angiosarcomas and KS) [1, 2]. As multifocality is a feature of KS, it may be difficult to differentiate multifocal KS (a tumor that has originated from a unique cellular clone, and grown in multiple locations in a single organ) from metastatic KS (which has originated from a unique cellular clone, and grown in multiple locations in a second organ). Section of right upper lobe of lung obtained during wedge biopsy demonstrating human herpesvirus 8 on immunohistochemical stain. AIDS-related KS is a low-grade vascular tumor caused by HHV-8. Although the incidence of HHV-8-induced KS has declined since the induction of ART, it remains one of the most common AIDS-defining malignancies (in addition to non-Hodgkin lymphoma) [3]. Although reported among all risk groups for HIV infection, KS is most common in men who have sex with men [4]. Typically, KS initially presents with mucocutaneous involvement including the skin, oral cavity, gastrointestinal tract, and respiratory system. However, one study of KS patients demonstrated that 37% of patients with visceral tumors had no evidence of skin or mucosal involvement [5]. Similarly, a study involving 168 patients with pulmonary KS stated that 15.5% lacked mucocutaneous involvement [6]. Combination ART is the treatment of choice for all HIV-infected patients with KS; however, patients with symptomatic visceral disease or pulmonary disease (such as our patient), regardless of viral load, should also receive chemotherapy [7, 8]. Liposomal anthracycline chemotherapy (most often pegylated liposomal doxorubicin) has been widely regarded to be the first-line treatment for pulmonary KS; however, other single-agent (paclitaxel, bleomycin, etoposide, vincristine, vinblastine, and vinorelbine) and combination chemotherapy agents (most widely doxorubicin, bleomycin, and vincristine) have been evaluated [7, 8]. A 2014 review noted that for patients on ART, there was no observed difference in liposomal doxorubicin, liposomal daunorubicin, or paclitaxel in patients with disease staged as T1 using the AIDS Clinical Trial Group (ACTG) staging system, which would include patients with pulmonary disease [7]. Additionally, initiating ART in HIV-infected patients with KS may pose a risk of immune reconstitution inflammatory syndrome, particularly if patients have signs of advanced HIV disease at the onset of ART [9]. The prognosis of patients with advanced-stage KS is influenced by multiple factors. A lower CD4 count and the presence of another AIDS-defined illness are associated with a poor prognosis of the disease [10]. One study demonstrated that the 5- and 10-year survival rates for patients with advanced-stage disease (defined as ACTG stage T1, and including but not limited to those with pulmonary disease), when treated, were 83% and 81%, respectively [11]. However, a smaller study following 25 patients with confirmed pulmonary KS showed a 5-year survival rate of 49%, and a median life expectancy of 1.6 years [12]. Unfortunately, in the present case, the patient likely developed pulmonary hemorrhage after video-assisted thoracoscopic surgery and continued to deteriorate rather quickly. Oncology was consulted, but the patient was not considered a candidate for chemotherapy due to his poor clinical status. The patient developed hypoxic respiratory failure requiring maximum ventilator settings. He was unable to be weaned from the ventilator and, ultimately, died 15 days after initial hospital presentation, only 10 months after being diagnosed with KS. The aggressive onset of disease in the present case makes KS important to consider in the differential diagnosis of HIV-infected immunocompromised patients who present with abdominal or pulmonary symptoms and with characteristic lung parenchymal abnormalities and lymphadenopathy on imaging. Interestingly, this patient never exhibited evidence of mucocutaneous involvement, which is typical in an initial presentation of KS. Acknowledgments. The authors thank Rongjun Guo, MD, PhD, in the Department of Pathology at the University of Alabama at Birmingham, for his assistance with the pathology figures presented in this report. Potential conflicts of interest. Dr. Muzny reports grants from NIH/NIAID outside the submitted work. All remaining authors: No reported conficts of interests. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Dr. Muzny reports grants from NIH/NIAID outside the submitted work.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/cix709
Institutions: University of Alabama at Birmingham, UAB Medicine
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: National Institutes of Health
OpenAlex ID: W2792004658
